{
}
Glenmark Pharmaceuticals reported a consolidated net profit of Rs 354.5 crore for Q2 FY25, rebounding from a loss of Rs 180.3 crore in the same quarter last year. Revenue from operations increased by 7.1% to Rs 3,433 crore, driven by strong performances in the Indian and European markets, particularly in cardiac and dermatology sectors. Despite a slight revenue drop in North America, the company’s EBITDA grew by 30.2% to Rs 601.9 crore, with margins at 17.5%.
Glenn Saldanha
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Glenmark Pharma reports strong Q2 profit driven by India and Europe markets
16:54 14.11.2024
Trending
Subcategory
Industry Trends
Corporate News
Startups & Entrepreneurship
Global Trade Developments
Retail and Consumer Goods
Stock Market Updates
Supply Chain Management
Government Economic Policies
Fintech Startups
Industry Mergers & Acquisitions
Private Equity Deals
Venture Capital Investments
CEO Changes
AI Applications
Funding Rounds & Investments
Economic Indicators
Emerging Startups
Corporate Social Responsibility
Inflation and Monetary Impact
AI Innovations
Countries:
Companies:
Apple Inc.
Grab2Go AS
Google Inc.
OLA ELECTRIC MOBILITY LTD
NVIDIA Corp
Amazon.com, Inc.
Microsoft Corporation
EFG Hermes Egypt
Broadcom Inc.
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
XIAOMI-W
Tesla, Inc.
LG CNS
Delhivery Limited
Ecom Express Ltd.
Scripbox.COM India Ltd.
SK hynix Inc.
Tesmec S.p.A.
OpenAI ERC USD
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Japanese Yen
Euro
United Arab Emirates Dirham
South Korean Won
Pakistani Rupee
Egyptian Pound
Saudi Riyal
Brazilian Real
Qatari Riyal
Indonesian Rupiah
Vietnamese Đồng
Hong Kong Dollar
Offshore Chinese Yuan
Canadian Dollar
Malaysian Ringgit
Swiss Franc
New Zealand Dollar
People: